Clinical trials for NON RARE IN EUROPE: Non-small cell lung cancer
68 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 2NCT06878274Post-operative Radiotherapy After Neodjuvant Chemo-immunotherapy and Surgery in Stage III NSCLCCentre hospitalier de l'Université de Montréal (CHUM)
- RECRUITINGPhase 3NCT07251582Effect of Infusion Timing on Pathologic Response to Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung CancerHunan Province Tumor Hospital
- RECRUITINGPhase 2NCT06946797A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)Bristol-Myers Squibb · PI: Bristol-Myers Squibb
- RECRUITINGPhase 2NCT07086456Combination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advanced Non-Small Cell Lung CancerSun Yat-sen University
- RECRUITINGN/ANCT07086300Electroacupuncture Combined With PD-1 Inhibitor for Elderly Patients With Advanced NSCLCKong Fanming
- RECRUITINGPhase 2NCT06620835Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by BrigatinibGroupe Francais De Pneumo-Cancerologie · PI: Jean-Bernard AULIAC
- RECRUITINGPHASE1, PHASE2NCT06922591Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC PatientsTango Therapeutics, Inc. · PI: Maxim Pimpkin, MD, PhD
- RECRUITINGPhase 3NCT07050043Low Dose Nivolumab With Chemotherapy vs Standard Chemotherapy as First-Line Treatment in Advanced or Metastatic NSCLCDr Arvindran A/L Alaga · PI: Dr. Arvindran A/L Alaga
- RECRUITINGPhase 3NCT06881784Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)Revolution Medicines, Inc.
- RECRUITINGPhase 4NCT07092202Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC With Leptomeningeal MetastasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology · PI: Xiaorong Dong, Dr
- RECRUITINGPhase 1NCT06868732Evaluation of JSKN016 Combination Therapy in Subjects With NSCLCJiangsu Alphamab Biopharmaceuticals Co., Ltd · PI: Li Zhang
- RECRUITINGNCT06809764Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)Daiichi Sankyo · PI: Project Manager
- RECRUITINGPhase 2NCT06926790Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)The First Affiliated Hospital of Guangzhou Medical University
- RECRUITINGNCT06626243Analysis of RATS, VATS and Open Lung Resections After Neoadjuvant Chemo-immunotherapy in Patients Performed in Five Referred CentersScientific Institute San Raffaele
- RECRUITINGPhase 1NCT06586515MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid TumorsEli Lilly and Company · PI: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
- RECRUITINGN/ANCT06752044Neoantigen-based Peptide Vaccine, PD-1 Inhibitor, and Radiotherapy for Advanced NSCLC Progressed After First-line TreatmentThe First Affiliated Hospital of Nanchang University
- RECRUITINGNCT06718972A Real-world Study on the Treatment of Non-small Cell Lung Cancer With Leptomeningeal Metastasis in ChinaGuangzhou Medical University
- RECRUITINGNCT06570317Nintedanib for the Prevention of Radiation Pneumonia in Unresectable NSCLCSecond Hospital of Shanxi Medical University · PI: Gang Jin, Dr.
- ACTIVE NOT RECRUITINGN/ANCT06461338Acupuncture for Enhancing Immunotherapy in Advanced NSCLC：a Pilot StudyGuangzhou University of Traditional Chinese Medicine · PI: Haibo Zhang, M.D.
- RECRUITINGN/ANCT06252129Maximizing Lymph Node Dissection on Fresh and Fixed Lung Cancer Resection SpecimensBrigham and Women's Hospital
- RECRUITINGPhase 2NCT06534762Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical StudyZhejiang Provincial People's Hospital · PI: Liu Yang, M.D.
- ACTIVE NOT RECRUITINGPhase 2NCT06448910Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLCFudan University
- ACTIVE NOT RECRUITINGN/ANCT06595498Next Generation Sequencing Method for the Detection of EGFR Gene Mutations in the Plasma of Patients With Lung CancerIstituto Oncologico Veneto IRCCS
- RECRUITINGPhase 2NCT06379087Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLCJi Yongling · PI: YongLing Ji, PhD
- RECRUITINGPhase 1NCT06431685Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung CancerSichuan University · PI: You Lu, MD
- RECRUITINGPHASE1, PHASE2NCT06114511A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung CancerSichuan Baili Pharmaceutical Co., Ltd. · PI: Li Zhang, PHD
- RECRUITINGPHASE1, PHASE2NCT06088771Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLCIcahn School of Medicine at Mount Sinai · PI: Thomas Marron, MD, PhD
- RECRUITINGPHASE1, PHASE2NCT05877430Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic CancerCJ Bioscience, Inc.
- RECRUITINGPhase 2NCT05948813TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain MetastasesTYK Medicines, Inc · PI: Yuankai Shi, MD
- RECRUITINGPhase 2NCT06001151Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) NegativeQian Chu · PI: Qian Chu
- RECRUITINGNCT06068049OSIREAL - Osimertinib RWE on EGFRm NSCLC in SpainAstraZeneca
- ACTIVE NOT RECRUITINGN/ANCT05703269Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving ImmunotherapyWake Forest University Health Sciences · PI: Glenn Lesser, MD
- RECRUITINGN/ANCT05987345Trial of Pulsed Electric Field Therapy in Patients With Late-stage Non-small Cell Lung CancerEnergenx Medical LTD. · PI: Shiyue Li, MD
- ACTIVE NOT RECRUITINGNCT06663020Impact of Smoking Cessation Duration on Postoperative Complications in Lung Cancer SurgeryCaner İşevi, MD
- RECRUITINGNCT05703516A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South KoreaNovartis Pharmaceuticals · PI: Novartis Pharmaceuticals
- RECRUITINGPHASE1, PHASE2NCT05933265Study of LP-184 in Patients With Advanced Solid TumorsLantern Pharma Inc. · PI: Reggie Ewesuedo, MD
- RECRUITINGNCT06833632Detection of Circulating Tumour Cells, Spread Through Air Space in Patients With Lung CancerIRCCS Azienda Ospedaliero-Universitaria di Bologna · PI: Pietro Bertoglio, MD
- ACTIVE NOT RECRUITINGN/ANCT05708599A Study to Compare Tissue and Liquid Biopsies in People With Different Types of CancerBoehringer Ingelheim
- RECRUITINGNCT05478538Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic PlatformElephas · PI: Fred Hausheer, MD, FACP
- RECRUITINGPhase 1NCT05581004A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid TumorsGenentech, Inc.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05546268Study of Oral MRT-2359 in Selected Cancer PatientsMonte Rosa Therapeutics, Inc
- RECRUITINGPhase 2NCT06065813Neoadjuvant Triprizumab and Radiotherapy in Operable Patients With Stage IIA-IIIA Non-small Cell Lung CancerNorthern Jiangsu People's Hospital
- ACTIVE NOT RECRUITINGPhase 3NCT05132075Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung CancerNovartis Pharmaceuticals · PI: Novartis Pharmaceuticals
- RECRUITINGPhase 2NCT05241028Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung CancerHebei Medical University Fourth Hospital
- RECRUITINGPhase 2NCT05061550Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerAstraZeneca · PI: Tina Cascone, MD
- RECRUITINGNCT05102110Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer.Origin Sciences · PI: Mr F McDermott, FRCS
- ACTIVE NOT RECRUITINGPhase 3NCT05015608Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET AmplificationHutchison Medipharma Limited · PI: Shun Lu, MD
- RECRUITINGNCT05037825The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid TumorsVastBiome
- RECRUITINGNCT05059951Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung CancerHunan Province Tumor Hospital · PI: Yongchang Zhang, MD
- RECRUITINGPhase 3NCT04853342To Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant ChemotherapyAllist Pharmaceuticals, Inc. · PI: Jianxing He, PHD
- RECRUITINGPHASE1, PHASE2NCT04686682A First-in-Human, JAB-8263 in Adult Patients With Advanced TumorsJacobio Pharmaceuticals Co., Ltd. · PI: Jacobio Pharmaceuticals
- ACTIVE NOT RECRUITINGPhase 2NCT04736823A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLCAkeso · PI: Li Zhang, MD
- ACTIVE NOT RECRUITINGNCT06243679The Efficacy and Safety of Adjuvant Immunotherapy After Pathological Complete Response Following Neoadjuvant Chemoimmunotherapy in Patients with Resectable NSCLCXiangya Hospital of Central South University
- ACTIVE NOT RECRUITINGPhase 3NCT04194944A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung CancerEli Lilly and Company · PI: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
- ACTIVE NOT RECRUITINGPhase 2NCT04166487Plasma-Adapted First-Line Pembro In NSCLCJulia K. Rotow, MD · PI: Julia K Rotow, MD
- ACTIVE NOT RECRUITINGPhase 2NCT03833440Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI ResistanceAssistance Publique Hopitaux De Marseille · PI: jean-olivier ARNAUD
- ACTIVE NOT RECRUITINGPhase 1NCT03893955A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid TumorsAbbVie · PI: ABBVIE INC.
- RECRUITINGNCT05701787Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare MutationsShanghai Chest Hospital · PI: Xiaomin Niu
- ACTIVE NOT RECRUITINGPhase 2NCT036206691st Line Durvalumab in PS 2 NSCLC PatientsSwiss Cancer Institute · PI: Michael Mark, MD
- ACTIVE NOT RECRUITINGNCT03705806Palliative Thoracic ImmunoRTUniversity Health Network, Toronto
- ACTIVE NOT RECRUITINGPhase 3NCT03519971Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung CancerAstraZeneca · PI: Jeffrey Bradley, MD
- ACTIVE NOT RECRUITINGPhase 1NCT03401385First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)Daiichi Sankyo Co., Ltd. · PI: Global Team Leader
- ACTIVE NOT RECRUITINGPhase 1NCT03875820Phase I Trial of Defactinib and VS-6766.Institute of Cancer Research, United Kingdom · PI: Udai Banerji, FRCP, PhD
- ACTIVE NOT RECRUITINGPhase 1NCT03220477Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.Memorial Sloan Kettering Cancer Center · PI: Kathryn Arbour, MD
- ACTIVE NOT RECRUITINGPhase 2NCT02314481Deciphering Antitumour Response and Resistance With INtratumour HeterogeneityUniversity College, London · PI: Charles Swanton
- RECRUITINGNCT03042221Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI TherapyUniversity of Colorado, Denver · PI: Erin Schenk
- ACTIVE NOT RECRUITINGPhase 3NCT02542293Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)AstraZeneca · PI: Gilberto de Castro
- ACTIVE NOT RECRUITINGPhase 3NCT02411448A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)Eli Lilly and Company · PI: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)